• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    IMPACT Therapeutics (SEHK:7630) Stock Price Sinks As Losses Trail Revenue Surge

    Simply Wall St·09/16/2026 11:31:34
    語音播報

    The market has been punishing IMPACT Therapeutics, with the share price down about 10% over the past week and close to 70% over three months. Yet the headline from these results is blunt: this is still a high-growth, loss-making biotech, and the revenue line is doing almost all the talking.

    H1 2026 revenue reached C¥105.19 million, well above the prior period, while the business still reported a net loss of C¥90.81 million. That mix of rapid sales expansion and continued red ink, sitting on a P/S of 23x, is what will matter for anyone thinking beyond today’s price move.

    Love IMPACT Therapeutics’ rapid top-line progress but uneasy about the ongoing losses and rich P/S tag? Check out the 621 high quality undiscovered gems for a list of high-growth companies with stronger fundamentals.

    H1 2026 Earnings Summary

    • Revenue (H1 2026 vs. H1 2025): C¥105.19 million vs. C¥25.236 million (very large increase, more than 4x)
    • Net Loss (H1 2026 vs. H1 2025): C¥90.81 million loss vs. C¥128.73 million loss (loss narrowed)
    • Basic EPS (H1 2026 vs. H1 2025): C¥0.369 loss per share vs. C¥0.578 loss per share (per share loss reduced)
    • Products by Clinical Stage (as of H2 2025, biotech pipeline breadth): 5 in Phase I, 4 in Phase II, 1 in Phase III, 1 in pre-registration, 1 approved

    Prefer clean visuals instead of scrolling through line after line of raw figures? See IMPACT Therapeutics’ full financial picture, including how the valuation compares with the current business profile, in the company report for IMPACT Therapeutics.

    SEHK:7630 Trailing 12-Month Earnings & Revenue History as at Sep 2026
    SEHK:7630 Trailing 12-Month Earnings & Revenue History as at Sep 2026

    Revenue Momentum Supports IMPACT Therapeutics Bulls

    For anyone leaning bullish on IMPACT Therapeutics, the headline is simple. Sales jumped from C¥25.236 million to C¥105.19 million in H1 2026. That is more than 4x in twelve months and speaks to real commercial traction around the oncology franchise. Net loss narrowed from C¥128.73 million to C¥90.81 million and basic EPS loss also shrank. You still have a biotech investing heavily, but the mix of rapid top line expansion and improving earnings trend supports the idea that this is more than a pure pipeline story.

    Losses And Cash Burn Still Temper Enthusiasm

    Bears will point straight to the income statement. IMPACT Therapeutics remains firmly loss making with a C¥90.81 million deficit in H1 2026, even after the improvement from C¥128.73 million. Per share loss of C¥0.369 also signals that cash burn is still meaningful for a company at this stage. Recent share price pressure, with the stock down over 10% in a week, 17% over a month and close to 70% over three months, shows that investors are treating execution risk and ongoing losses as live issues, not background noise.

    Compare IMPACT Therapeutics’ rapid revenue ramp and narrowing losses with how the street is framing the story. See the consensus price target analysis for IMPACT Therapeutics to check whether analysts think the current HK$11.27 price already reflects that progress or still leaves room for a different outcome.

    Stay Ahead Of The Next Move

    After a week where IMPACT Therapeutics has been hit hard despite rapid revenue progress, it can help to track the story rather than just react to price. Register for free with Simply Wall St and add it to your Watchlist so you can monitor share price against fair value and wait for an entry point that fits your plan. Once you are invested, keep your holdings organised inside the Portfolio Command Center, which filters out market noise and surfaces only the most important developments. Over the long haul, lean on the Community to see how other investors are thinking about the same risks and opportunities. This can help you spot potential catalysts or red flags early and stay a step ahead of the market.

    Seeking Alternatives Beyond IMPACT Therapeutics?

    Fresh ideas can move fast. Some stocks are building breakout momentum, while others are quietly dropping into potentially attractive territory under the radar for now. Consider exploring opportunities early.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.